Evidence map›Paper›PMID 33512774›Full record

ArticleJournal of cellular and molecular medicine2021

Inhibition of hepatocyte nuclear factor 1β contributes to cisplatin nephrotoxicity via regulation of nf-κb pathway.

Yan Zhang, Jielu Hao, Zijun Du, Peiyao Li, Jinghua Hu, Mengna Ruan, Shulian Li, Yuanfang Ma, Qiang Lou

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yan ZhangJoint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China.
Jielu HaoDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Zijun DuJoint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China.
Peiyao LiJoint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China.
Jinghua HuDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Mengna RuanDepartment of Nephrology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Shulian LiJoint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China.
Yuanfang MaJoint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China.
Qiang LouJoint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China.ORCID 0000-0002-8253-0691
Henan University · CNMayo Clinic in Arizona · USSecond Military Medical University · CN

Funding

Pilot and FeasibilityP30DK090728 · NIDDK · MAYO CLINIC ROCHESTER · PI TORRES, VICENTE E · 2010 to 2019
$11.8M
Molecular dissection of the ciliary gateR01DK099160 · NIDDK · MAYO CLINIC ROCHESTER · PI Jinghua Hu · 2014 to 2026
$4.0M
Henan University 2019004 and zzjj20140053Key Scientific and Technological Project of Henan Province 202102310380 and 192102310314National Natural Science Foundation of China 81970592, U1404826 and 81700593NIDDK NIH HHS P30 DK090728NIDDK NIH HHS R01 DK099160
6 · The paper itself

Abstract

Cisplatin nephrotoxicity has been considered as serious side effect caused by cisplatin-based chemotherapy. Recent evidence indicates that renal tubular cell apoptosis and inflammation contribute to the progression of cisplatin-induced acute kidney injury (AKI). Hepatocyte nuclear factor 1β (HNF1β) has been reported to regulate the development of kidney cystogenesis, diabetic nephrotoxicity, etc However, the regulatory mechanism of HNF1β in cisplatin nephrotoxicity is largely unknown. In the present study, we examined the effects of HNF1β deficiency on the development of cisplatin-induced AKI in vitro and in vivo. HNF1β down-regulation exacerbated cisplatin-induced RPTC apoptosis by indirectly inducing NF-κB p65 phosphorylation and nuclear translocation. HNF1β knockdown C57BL/6 mice were constructed by injecting intravenously with HNF1β-interfering shRNA and PEI. The HNF1β scramble and knockdown mice were treated with 30 mg/kg cisplatin for 3 days to induce acute kidney injury. Cisplatin treatment caused increased caspase 3 cleavage and p65 phosphorylation, elevated serum urea nitrogen and creatinine, and obvious histological damage of kidney such as fractured tubules in control mice, which were enhanced in HNF1β knockdown mice. These results suggest that HNF1β may ameliorate cisplatin nephrotoxicity in vitro and in vivo, probably through regulating NF-κB signalling pathway.

Indexed as

Acute Kidney InjuryAnimalsAntineoplastic AgentsApoptosisCisplatinDisease Models, AnimalHepatocyte Nuclear Factor 1-betaKidney TubulesMiceMice, KnockoutNephronsNF-kappa BPhosphorylationRatsSignal TransductionTranscription Factor RelAAntineoplastic AgentsCisplatinHepatocyte Nuclear Factor 1-betaHNF1B protein, humanNF-kappa BTranscription Factor RelAcisplatin nephrotoxicityHepatocyte nuclear factor 1βNF-κB

Identifiers

PMID33512774
PMCPMC7957194
OpenAlexW3121485877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.